LAM Therapeutics, Inc.

LAM Therapeutics, Inc. is a biotechnology company focused on developing precision therapeutics for treating cancer and rare diseases through advanced technologies and targeted drug candidates. Founded in 2013 and headquartered in the United States, LAM Therapeutics, Inc. specializes in precision therapeutics.

The company has conducted two deals, with the most recent being a Series C funding round on March 30, 2017, raising USD 58. 00 mn. Brigette Roberts serves as CEO, leading the firm since its inception and emphasizing its commitment to innovative treatment solutions. LAM Therapeutics specializes in the development of precision therapeutics aimed at treating cancer and rare diseases.

The company has three main drug candidates currently in clinical trials: LAM-001, an inhaled mTOR kinase inhibitor designed for lymphangioleiomyomatosis; LAM-002, a selective PIKfyve kinase inhibitor targeting B-cell non-Hodgkin lymphoma; and LAM-003, an orally active small molecule immuno-modulatory drug for acute myeloid leukemia. Each product leverages advanced technologies such as next-generation sequencing and deep learning to improve patient outcomes by matching therapeutics to individual genetic profiles. LAM Therapeutics targets markets in North America, Europe, and parts of Asia, addressing the needs of healthcare providers, oncologists, and patients suffering from these conditions. LAM Therapeutics operates on a transactional model that revolves around partnerships with healthcare providers and clinical trial collaborations.

The company engages with hospitals and clinical research organizations to facilitate the testing and eventual commercialization of its therapeutics. Revenue streams include milestone payments associated with the progression of clinical trials and potential licensing agreements once products are approved for market entry. Their flagship offerings, LAM-001 and LAM-002, are positioned to provide advancements in oncology, enhancing their appeal to healthcare systems and pharmaceutical partners seeking innovative treatment options. LAM Therapeutics plans to utilize the USD 58.

00 mn raised in the Series C funding to support the advancement of its drug candidates through clinical trials and to explore further market opportunities. The company aims to expand its product offerings and intends to launch LAM-001, LAM-002, and LAM-003 in targeted global markets within the next few years. Specific regions targeted for expansion include additional areas in Asia and Europe by 2025, supporting their initiative to meet growing healthcare demands.